Jump to content

Pubmed-EFFICACY OF ORAL PSYLLIUM IN PEDIATRIC IRRITABLE BOWEL SYNDROME : A DOUBLE BLIND RANDOMISED CONTROL TRIAL


Health Reporter
 Share

Recommended Posts

J Pediatr Gastroenterol Nutr. 2022 Sep 22. doi: 10.1097/MPG.0000000000003622. Online ahead of print.

ABSTRACT

OBJECTIVE: Pediatric irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with variable response to various therapeutic agents. Psyllium has been proven to be effective in adults; however, there is no study in children. To evaluate the efficacy of psyllium husk as compared to placebo in Pediatric IBS patients.

METHODS: In this double blind Randomized controlled trial, 43 children were assigned to psyllium arm (Group A) and 38 into placebo arm (Group B). Severity is assessed at baseline and after 4 weeks of treatment using IBS severity scale (IBS-SSS) and classified into mild, moderate and severe categories. Categorical data was compared with Chi-square test and paired categorical variable was compared with Mc Nemer's test.

RESULTS: Mean ages (±SD; in years) of group A and B were 9.87 (2.7) and 9.82 (3.17) respectively with median duration of illness of 12 months. At baseline, type, severity and parameters (IBS-SSS) of IBS were equally distributed in two groups. There was a significant reduction in median (IQR) of total IBS SSS in Psyllium versus placebo [75(42.5-140) vs. 225(185-270); P< 0.001] at 4 weeks. Similarly 43.9% in Group A vs. 9.7% in Group B attained remission [IBS-SSS < 75 (p < 0.0001)]. The mean difference in IBS-SSS between group A and group B was -122.85 with risk ratio of 0.64 (95% CI; 0.42, 0.83; P= 0.001) and absolute risk reduction of 32% (NNT = 3).

CONCLUSION: Psyllium husk is effective for the therapy of Pediatric IBS when compared with placebo in short term.

PMID:36136861 | DOI:10.1097/MPG.0000000000003622

View the full article


Link to post
Share on other sites

 Share

×
×
  • Create New...